(Source: BJU International)MedWorm Message: Register for MedMatcha, MedWorm's medical advertising network, and receive $5 free advertising.

(Source: International Journal of Urology)

MINNEAPOLIS, Aug. 24, 2010 (GLOBE NEWSWIRE) -- Urologix(r), Inc. (Nasdaq:ULGX), a medical device company that develops, manufactures and markets minimally invasive Cooled ThermoTherapy(tm) technology to urologists to provide a durable and effective in-office treatment for patients suffering from benign prostatic hyperplasia (BPH), today reported financial results for its fourth quarter ended June 30, 2010 and for fiscal year 2010. (Source: Medical News (via PRIMEZONE))

Objectives:  (Source: International Journal of Urology)

As men age, the prostate enlarges over time obstructing the prostatic urethra and interfering with sphincter function. The resulting condition, known as benign prostatic hyperplasia (BPH), is associated with decreased peak urinary flow rate... (Source: Food and Drug Adminstration (FDA): CDRHNew)

Authors: Djavan B, Eckersberger E, Finkelstein J, Espinosa G, Sadri H, Brandner R, Shah O, Lepor H Benign prostatic hyperplasia (BPH) is the most common benign adenoma in men, affecting nearly all of them. BPH represents a clinically significant cause of bladder outflow obstruction in up to 40% of men. The growing frequency of diagnosis is due to increasing life expectancy and a trend toward seeking medical advice at earlier stages of the disease. The last decade has witnessed a significant shift in emphasis in the management of BPH, with medical therapies and, to a lesser extent, minimally invasive therapies becoming the predominant active therapy choices. The development of effective therapies such as alpha-adrenergic blockers and 5-alpha-reductase inhibitors and the possibility of t...MedWorm Message: Register for MedMatcha, MedWorm's medical advertising network, and receive $5 free advertising.

Authors: Sharp VJ, Takacs EB, Powell CR Prostatitis ranges from a straightforward clinical entity in its acute form to a complex, debilitating condition when chronic. It is often a source of frustration for the treating physician and patient. There are four classifications of prostatitis: acute bacterial, chronic bacterial, chronic prostatitis/chronic pelvic pain syndrome, and asymptomatic. Diagnosis of acute and chronic bacterial prostatitis is primarily based on history, physical examination, urine culture, and urine specimen testing pre- and post-prostatic massage. The differential diagnosis of prostatitis includes acute cystitis, benign prostatic hyperplasia, urinary tract stones, bladder cancer, prostatic abscess, enterovesical fistula, and foreign body within the urinary tract. T...

The Scottish Medicines Consortium has approved Combodart (dutasteride 0.5mg/tamsulosin hydrochloride 0.4mg) for the treatment of benign prostatic hyperplasia (BPH) within NHS Scotland. (Source: Nursing Times Breaking News)

Benign prostatic hyperplasia (BPH) is the most common benign adenoma in men, affecting nearly all of them. BPH represents a clinically significant cause of bladder outflow obstruction in up to 40% of men. The growing frequency of diagnosis is due to increasing life expectancy and a trend toward seeking medical advice at earlier stages of the disease. The last decade has witnessed a significant shift in emphasis in the management of BPH, with medical therapies and, to a lesser extent, minimally invasive therapies becoming the predominant active therapy choices. The development of effective therapies such as alpha-adrenergic blockers and 5-alpha-reductase inhibitors and the possibility of their combined use represent the most significant advance in the treatment of BPH. (Source: Primary Care...

MINNEAPOLIS, Aug. 10, 2010 --(HSMN NewsFeed) -- Urologix(R), Inc. (Nasdaq:ULGX ), a medical device company that develops, manufactures and markets minimally invasive Cooled ThermoTherapy(TM) technology to urologists to provide a durable and effective in-of... Devices, Urology, PersonnelUrologix, Cooled ThermoTherapy, benign prostatic hyperplasia (Source: HSMN NewsFeed)

CONCLUSIONS: Changes in glycosylation of PSA were identified using 50mul of serum with PSA in the range of 4-10ng/ml, this represents a more specific and sensitive test for PCa based on fucosylation changes of fPSA. PMID: 20708609 [PubMed - as supplied by publisher] (Source: International Journal of Clinical Chemistry)MedWorm Message: Register for MedMatcha, MedWorm's medical advertising network, and receive $5 free advertising.

MINNEAPOLIS, Aug. 10, 2010 (GLOBE NEWSWIRE) -- Urologix(r), Inc. (Nasdaq:ULGX), a medical device company that develops, manufactures and markets minimally invasive Cooled ThermoTherapy(tm) technology to urologists to provide a durable and effective in-office treatment for patients suffering from benign prostatic hyperplasia (BPH), announced Christopher R. Barys has joined the Board of Directors effective August 6, 2010. (Source: Medical News (via PRIMEZONE))

GlaxoSmithKline (GSK) announced today that the Scottish Medicines Consortium (SMC) has accepted Combodart® (dutasteride 0.5mg/ tamsulosin hydrochloride 0.4mg) for use within NHS Scotland. Combodart is the first fixed dose combination of a 5-alpha reductase inhibitor, dutasteride and an alpha blocker, tamsulosin hydrochloride. It is indicated for the treatment of moderate-to-severe benign prostatic hyperplasia (BPH) and reduction in the risk of acute urinary retention (AUR) and BPH-related surgery... (Source: Health News from Medical News Today)

ANDROGEN DEPRIVATION INDUCES RAPID INVOLUTION AND RECOVERY OF HUMAN PROSTATE VASCULATURE. Am J Physiol Endocrinol Metab. 2010 Aug 10; Authors: Godoy A, Montecinos VP, Gray DR, Sotomayor P, Yau JM, Vethanayagam RR, Singh S, Mohler JL, Smith GJ The response of the prostate tissue microenvironment to androgen deprivation (AD) represents a critical component in the treatment of benign prostatic hyperplasia and prostate cancer (CaP). Primary xenografts of human benign and CaP tissue transplanted to immunocompromised SCID mice were utilized to characterize the response of the prostate vasculature during the initial fourteen days of AD. Microvessel density and vascular lumen diameter in the prostate xenografts decreased rapidly after AD, reached a nadir on Days 2-4, and recovered betw...

Abstract (Source: The Prostate)

CONCLUSION: Determination of f/tPSA ratio improves differentiation of Pca from BPH. We recommend a cut-off value of 0.14 to be applied to Iranian patients. PMID: 20535696 [PubMed - in process] (Source: Urology Journal)MedWorm Message: Register for MedMatcha, MedWorm's medical advertising network, and receive $5 free advertising.

CONCLUSION: Transurethral prostate resection has been introduced as the surgical treatment of choice in patients with benign prostatic hyperplasia. However, open prostatectomy still has a place. Suprapubic prostatectomy with no bladder drainage and no bladder neck suture appeared to be successful in decreasing convalescence and hospitalization times, with no significant complication, major blood loss, or bladder neck contracture. PMID: 20209457 [PubMed - indexed for MEDLINE] (Source: Urology Journal)

Conclusions: A covered, retrievable, barbed prostatic stent seems to be feasible for use in hormone-induced canine BPH. The stent induced prostatic urethral dilatation, and extensive prostatic glandular atrophy persisted up to 8 weeks after stent removal. (Source: Journal of Vascular and Interventional Radiology : JVIR)

This study was conducted to examine whether simultaneous transrectal prostate needle biopsy (TPNB) due to an increase in PSA levels is safe and effective in patients who are scheduled for transurethral resection of the prostate (TURP) for benign prostate hyperplasia (BPH). Combined TPNB and TURP was performed in a total of 42 patients aged � 60 years who had gray zone PSA (4-10 ng/ml) and PSA density (PSAD) values of � 0.12. The frequencies of fever, sepsis and epididymitis were assessed after surgery... (Source: Health News from Medical News Today)

This study was conducted to examine whether simultaneous transrectal prostate needle biopsy (TPNB) due to an increase in PSA levels is safe and effective in patients who are scheduled for transurethral resection of the prostate (TURP) for benign prostate hyperplasia (BPH). Combined TPNB and TURP was performed in a total of 42 patients aged = 60 years who had gray zone PSA (4-10 ng/ml) and PSA density (PSAD) values of Six (14... (Source: Health News from Medical News Today)